---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-040225"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2026-06-03T20:07:02+00:00"
generated_at: "2026-06-03T20:36:02.025309+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mineralys prices $150M common stock offering at $26.50/sh; proceeds to fund royalty repurchase

## Summary
- 5,660,378 shares at $26.50/share; gross proceeds ~$150M, net ~$142.5M.
- Proceeds to partially fund $200M upfront payment to repurchase royalty obligation from Tanabe Pharma.
- Offering expected to close June 4, 2026; joint book-runners: BofA, Goldman Sachs, Evercore ISI.
- Company separately announced a $500M committed debt facility with Pharmakon Advisors.
- Underwriters purchased at $25.3075/share; shelf registration effective on filing.

## SEC filing metadata
- accession: 0001628280-26-040225
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2026-06-03T20:07:02+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000162828026040225/0001628280-26-040225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000162828026040225/mlys-20260603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-040225
- JSON: https://secwatch.observer/filing/0001628280-26-040225.json
- Plain text: https://secwatch.observer/filing/0001628280-26-040225.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.